Welcome to the April edition of Going on Trial, a monthly newsletter covering clinical trials and drug development for autism and related conditions.In this issue, we're talking about a serotonin agonist's path to trial for autism, debate around a trial of psilocybin for fragile X syndrome and an analysis of placebo responses in a clinical trial of the vasopressin blocker balovaptan.Feel free...
Five different psychedelic drugs share the ability to restore the mature brain to a developmental state during which it can more easily adjust its connections and learn new information, a new study suggests.Mice treated with the psychedelics were better able to learn from social experiences and showed changes in the brain's reward center, the researchers found.The results hint at a common...
Going on Trial rounds up new developments in autism-related drug trials. This month we’re revisiting decade-old data from a trial of arbaclofen for fragile X syndrome and looking into a new implant-based approach to quelling seizures, among other treatment strategies.